Cost-effectiveness analysis of irinotecan hydrochloride liposome in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma
When using three times per capita GDP of China in 2023 as the WTP threshold, the irinotecan hydrochloride liposome plus chemotherapy regimen is not considered cost-effective compared to the standard 5-FU/LV regimen.
Authors
- PanFeng Feng
- ShaoQing Zhan (ORCID: https://orcid.org/0009-0001-5763-4798)
Institutions
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
- Second People's Hospital of NanTong (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-12
- DOI
- https://doi.org/10.3389/fphar.2025.1596658
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jiangsu Pharmaceutical Association
- Nanjing Medical University